We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-27.9%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$158M
AUM Growth
-$103M
Cap. Flow
-$24.7M
Cap. Flow %
-15.62%
Top 10 Hldgs %
99.18%
Holding
15
New
1
Increased
–
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
XCUR icon
Exicure
XCUR
+$15.9M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$25.9M
2
AVDR
Avedro, Inc Common Stock
AVDR
+$14.1M
3
CHMA
Chiasma, Inc. Common Stock
CHMA
+$610K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PSNL icon
1
Personalis
PSNL
$1.41B
$79.9M 50.55%
5,449,294
– –
CRSP icon
2
CRISPR Therapeutics
CRSP
$4.75B
$25.7M 16.28%
628,398
-542,870
-46% -$25.9M
XCUR icon
3
Exicure
XCUR
$12.3M
$15.8M 9.96%
+41,667
New +$15.9M
SIEN
4
DELISTED
Sientra, Inc.
SIEN
$15.5M 9.78%
239,084
– –
SLNO
5
DELISTED
Soleno Therapeutics
SLNO
$6.91M 4.37%
311,285
– –
PRTK
6
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.51M 2.85%
1,041,131
– –
VRNA
7
DELISTED
Verona Pharma
VRNA
$4.12M 2.61%
901,943
– –
SYRE icon
8
Spyre Therapeutics
SYRE
$8.67B
$1.85M 1.17%
9,620
– –
CHMA
9
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.83M 1.16%
370,671
-107,535
-22% -$610K
OBSV
10
DELISTED
ObsEva SA Ordinary Shares
OBSV
$731K 0.46%
87,999
– –
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$670K 0.42%
131,036
– –
TARA icon
12
Protara Therapeutics
TARA
$230M
$525K 0.33%
50,447
– –
SRRA
13
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$83K 0.05%
5,417
– –
OCGN icon
14
Ocugen
OCGN
$450M
$20K 0.01%
7,111
– –
AVDR
15
DELISTED
Avedro, Inc Common Stock
AVDR
– –
-719,402
Closed -$14.1M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q3 2019 Portfolio in Review

As of Q3 2019, Abingworth held 15 positions worth $158M, down 39% from $261M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Abingworth withdrew a net $24.7M in Q3 2019, closing 1 position and reducing 2 holdings. Its most notable exit was Avedro, Inc Common Stock, an estimated $14.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Abingworth opened a new position in Exicure worth $15.8M.

  • Abingworth's largest Q3 2019 buy was Exicure: 41,667 shares worth $15.8M.
  • Abingworth's biggest Q3 2019 reduction was CRISPR Therapeutics, cutting an estimated $25.9M.
  • Abingworth fully exited Avedro, Inc Common Stock in Q3 2019, selling an estimated $14.1M.
  • Abingworth's ten largest holdings make up 99% of its $158M portfolio in Q3 2019.
  • Abingworth opened 1 new position and closed 1 in Q3 2019.
  • Abingworth's portfolio value fell 39% quarter-over-quarter to $158M.

Based on Abingworth's 13F filing for Q3 2019, filed 14 Nov 2019.